$VRTX News

Vertex Pharmaceuticals Q2 Earnings Call Highlights

Vertex (VRTX) Reports Q2 Earnings: What Key Metrics Have to Say

Vertex Pharmaceuticals (VRTX) Q2 Earnings Lag Estimates

Vertex Raises 2026 Guidance, But Shares Dip For One Key Reason

Vertex Pharmaceuticals (NASDAQ:VRTX) Beats Q2 CY2026 Sales Expectations, Full-Year Outlook Slightly Exceeds Expectations

Vertex Reports Second Quarter 2026 Financial Results

Vertex Pharmaceuticals Raises FY2026 Sales Guidance from $12.950B-$13.100B to $13.100B-$13.200B vs $13.065B Est

Vertex Pharmaceuticals Q2 Adj. EPS $4.73, Inline, Sales $3.334B Beat $3.232B Estimate

Vertex Pharmaceuticals (VRTX) Q2 Earnings Report Preview: What To Look For

Vertex Pharmaceuticals (VRTX) Expands Its Pipeline Reach, Is The Stock Fully Valued?

Vertex Pharmaceuticals (VRTX) Stock Looks Like A Bargain At This Price

Vertex (VRTX) Q2 Earnings Preview: What You Should Know Beyond the Headline Estimates

Vertex Pharmaceuticals (NASDAQ:VRTX): Strong Growth and Textbooks Technical Setup for Breakout

Vertex Pharmaceuticals (VRTX) Exceeds Market Returns: Some Facts to Consider

Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know

Chris Young, Vertex CEO: A Fortt Knox Conversation

Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: Should You Buy?

Vertex Pharmaceuticals (VRTX) Sees a More Significant Dip Than Broader Market: Some Facts to Know

Vertex was sole bidder in high-premium Crinetics acquisition

Vertex Pharmaceuticals (NASDAQ:VRTX): An Affordable Growth Stock Balancing Strong Fundamentals With Reasonable Valuation